MYCN-mediated Transcriptional Repression in Neuroblastoma: the Other Side of the Coin

Overview

Journal Front Oncol

Specialty Oncology

Date 2013 Mar 14

PMID 23482921

Citations 30

Authors

Samuele Gherardi

Emanuele Valli

Daniela Erriquez

Giovanni Perini

Affiliations

Soon will be listed here.

Abstract

Neuroblastoma is the most common extra cranial solid tumor in childhood and the most frequently diagnosed neoplasm during the infancy. MYCN amplification and overexpression occur in about 25% of total neuroblastoma cases and this percentage increases at 30% in advanced stage neuroblastoma. So far, MYCN expression profile is still one of the most robust and significant prognostic markers for neuroblastoma outcome. MYCN is a transcription factor that belongs to the family of MYC oncoproteins, comprising c-MYC and MYCL genes. Deregulation of MYC oncoprotein expression is a crucial event involved in the occurrence of different types of malignant tumors. MYCN, as well as c-MYC, can heterodimerize with its partner MAX and activate the transcription of several target genes containing E-Box sites in their promoter regions. However, recent several lines of evidence have revealed that MYCN can repress at least as many genes as it activates, thus proposing a novel function of this protein in neuroblastoma biology. Whereas the mechanism by which MYCN can act as a transcriptional activator is relatively well known, very few studies has been done in the attempt to explain how MYCN can exert its transcription repression function. Here, we will review current knowledge about the mechanism of MYCN-mediated transcriptional repression and will emphasize its role as a repressor in the recruitment of a precise set of proteins to form complexes capable of down-regulating specific subsets of genes whose function is actively involved in apoptosis, cell differentiation, chemosensitivity, and cell motility. The finding that MYCN can also act as a repressor has widen our view on its role in oncogenesis and has posed the bases to search for novel therapeutic drugs that can specifically target its transcriptional repression function.

Citing Articles

MYCN drives oncogenesis by cooperating with the histone methyltransferase G9a and the WDR5 adaptor to orchestrate global gene transcription.

Liu Z, Zhang X, Xu M, Hong J, Ciardiello A, Lei H PLoS Biol. 2024; 22(3):e3002240.

PMID: 38547242 PMC: 11003700. DOI: 10.1371/journal.pbio.3002240.

Irrespective of Plaque Activity, Multiple Sclerosis Brain Periplaques Exhibit Alterations of Myelin Genes and a TGF-Beta Signature.

Nataf S, Guillen M, Pays L Int J Mol Sci. 2022; 23(23).

PMID: 36499320 PMC: 9738407. DOI: 10.3390/ijms232314993.

MYCN Impact on High-Risk Neuroblastoma: From Diagnosis and Prognosis to Targeted Treatment.

Bartolucci D, Montemurro L, Raieli S, Lampis S, Pession A, Hrelia P Cancers (Basel). 2022; 14(18).

PMID: 36139583 PMC: 9496712. DOI: 10.3390/cancers14184421.

A Focus on Regulatory Networks Linking MicroRNAs, Transcription Factors and Target Genes in Neuroblastoma.

Perri P, Ponzoni M, Corrias M, Ceccherini I, Candiani S, Bachetti T Cancers (Basel). 2021; 13(21).

PMID: 34771690 PMC: 8582685. DOI: 10.3390/cancers13215528.

MYC protein interactors in gene transcription and cancer.

Lourenco C, Resetca D, Redel C, Lin P, MacDonald A, Ciaccio R Nat Rev Cancer. 2021; 21(9):579-591.

PMID: 34188192 DOI: 10.1038/s41568-021-00367-9.

References

Otto T, Horn S, Brockmann M, Eilers U, Schuttrumpf L, Popov N . Stabilization of N-Myc is a critical function of Aurora A in human neuroblastoma. Cancer Cell. 2008; 15(1):67-78. DOI: 10.1016/j.ccr.2008.12.005. View

Shimono A, Okuda T, Kondoh H . N-myc-dependent repression of ndr1, a gene identified by direct subtraction of whole mouse embryo cDNAs between wild type and N-myc mutant. Mech Dev. 1999; 83(1-2):39-52. DOI: 10.1016/s0925-4773(99)00025-8. View

Ochiai H, Takenobu H, Nakagawa A, Yamaguchi Y, Kimura M, Ohira M . Bmi1 is a MYCN target gene that regulates tumorigenesis through repression of KIF1Bbeta and TSLC1 in neuroblastoma. Oncogene. 2010; 29(18):2681-90. DOI: 10.1038/onc.2010.22. View

Lutz W, Stohr M, SCHURMANN J, Wenzel A, Lohr A, Schwab M . Conditional expression of N-myc in human neuroblastoma cells increases expression of alpha-prothymosin and ornithine decarboxylase and accelerates progression into S-phase early after mitogenic stimulation of quiescent cells. Oncogene. 1996; 13(4):803-12. View

Chesler L, Schlieve C, Goldenberg D, Kenney A, Kim G, McMillan A . Inhibition of phosphatidylinositol 3-kinase destabilizes Mycn protein and blocks malignant progression in neuroblastoma. Cancer Res. 2006; 66(16):8139-46. PMC: 2924674. DOI: 10.1158/0008-5472.CAN-05-2769. View

Park D, Razani B, Lasorella A, Schreiber-Agus N, Pestell R, Iavarone A . Evidence that Myc isoforms transcriptionally repress caveolin-1 gene expression via an INR-dependent mechanism. Biochemistry. 2001; 40(11):3354-62. DOI: 10.1021/bi002787b. View

Burnichon N, Cascon A, Schiavi F, Morales N, Comino-Mendez I, Abermil N . MAX mutations cause hereditary and sporadic pheochromocytoma and paraganglioma. Clin Cancer Res. 2012; 18(10):2828-37. DOI: 10.1158/1078-0432.CCR-12-0160. View

Nie Z, Hu G, Wei G, Cui K, Yamane A, Resch W . c-Myc is a universal amplifier of expressed genes in lymphocytes and embryonic stem cells. Cell. 2012; 151(1):68-79. PMC: 3471363. DOI: 10.1016/j.cell.2012.08.033. View

Marshall G, Gherardi S, Xu N, Neiron Z, Trahair T, Scarlett C . Transcriptional upregulation of histone deacetylase 2 promotes Myc-induced oncogenic effects. Oncogene. 2010; 29(44):5957-68. DOI: 10.1038/onc.2010.332. View

10.

Gartel A, Ye X, Goufman E, Shianov P, Hay N, Najmabadi F . Myc represses the p21(WAF1/CIP1) promoter and interacts with Sp1/Sp3. Proc Natl Acad Sci U S A. 2001; 98(8):4510-5. PMC: 31865. DOI: 10.1073/pnas.081074898. View

11.

Ribatti D, Marimpietri D, Pastorino F, Brignole C, Nico B, Vacca A . Angiogenesis in neuroblastoma. Ann N Y Acad Sci. 2005; 1028:133-42. DOI: 10.1196/annals.1322.014. View

12.

Jakobovits A, Schwab M, Bishop J, Martin G . Expression of N-myc in teratocarcinoma stem cells and mouse embryos. Nature. 1985; 318(6042):188-91. DOI: 10.1038/318188a0. View

13.

Schulte J, Horn S, Otto T, Samans B, Heukamp L, Eilers U . MYCN regulates oncogenic MicroRNAs in neuroblastoma. Int J Cancer. 2007; 122(3):699-704. DOI: 10.1002/ijc.23153. View

14.

Valentijn L, Koppen A, van Asperen R, Root H, Haneveld F, Versteeg R . Inhibition of a new differentiation pathway in neuroblastoma by copy number defects of N-myc, Cdc42, and nm23 genes. Cancer Res. 2005; 65(8):3136-45. DOI: 10.1158/0008-5472.CAN-04-2469. View

15.

Nagy J, Dvorak A, Dvorak H . VEGF-A and the induction of pathological angiogenesis. Annu Rev Pathol. 2007; 2:251-75. DOI: 10.1146/annurev.pathol.2.010506.134925. View

16.

Veschi V, Petroni M, Cardinali B, Dominici C, Screpanti I, Frati L . Galectin-3 impairment of MYCN-dependent apoptosis-sensitive phenotype is antagonized by nutlin-3 in neuroblastoma cells. PLoS One. 2012; 7(11):e49139. PMC: 3494673. DOI: 10.1371/journal.pone.0049139. View

17.

Beenken A, Mohammadi M . The FGF family: biology, pathophysiology and therapy. Nat Rev Drug Discov. 2009; 8(3):235-53. PMC: 3684054. DOI: 10.1038/nrd2792. View

18.

Zhang X, Zhao X, Fiskus W, Lin J, Lwin T, Rao R . Coordinated silencing of MYC-mediated miR-29 by HDAC3 and EZH2 as a therapeutic target of histone modification in aggressive B-Cell lymphomas. Cancer Cell. 2012; 22(4):506-523. PMC: 3973134. DOI: 10.1016/j.ccr.2012.09.003. View

19.

Cohn S, Pearson A, London W, Monclair T, Ambros P, Brodeur G . The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report. J Clin Oncol. 2008; 27(2):289-97. PMC: 2650388. DOI: 10.1200/JCO.2008.16.6785. View

20.

De Brouwer S, Mestdagh P, Lambertz I, Pattyn F, De Paepe A, Westermann F . Dickkopf-3 is regulated by the MYCN-induced miR-17-92 cluster in neuroblastoma. Int J Cancer. 2011; 130(11):2591-8. DOI: 10.1002/ijc.26295. View